ASX LIMITED (ASX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ASX

ASX - ASX LIMITED

Year End: June
GICS Industry Group : Diversified Financials
Debt/EBITDA: 10.31
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

The Australian Securities Exchange is Australia's primary securities exchange. The ASX was formed in 1987 as an amalgamation of the six states securities exchanges. It oversees compliance with its operating rules and standards of corporate governance among its listed entities.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$70.39

25 Jul
2025

0.000

OPEN

$70.39

0.000

HIGH

$70.39

0

LOW

$70.39

TARGET
$66.033 -6.2% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AEF . AMP . BVS . CGF . CVW . DJW . ENN . GDG . GQG . HMC . HUB . IFL . IFT . IRE . KAM . KSL . MAF . MFG . MQG . NGI . NWL . PAC . PNI . PPS . PPT . PTM . QAL . RPL . RZI . WHF .
FNARENA'S MARKET CONSENSUS FORECASTS
ASX: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx 244.8 264.9 xxx
DPS (cps) xxx 208.0 224.1 xxx
EPS Growth xxx 49.4% 8.2% xxx
DPS Growth xxx - 8.9% 7.7% xxx
PE Ratio xxx N/A 26.3 xxx
Dividend Yield xxx N/A 3.2% xxx
Div Pay Ratio(%) xxx 85.0% 84.6% xxx

Dividend yield today if purchased 3 years ago: 2.41%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.95

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 21/08 - ex-div 106.80c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx244.8
DPS All xxxxxxxxxxxxxxx208.0
Sales/Revenue xxxxxxxxxxxxxxx1,590.7 M
Book Value Per Share xxxxxxxxxxxxxxx1,921.2
Net Operating Cash Flow xxxxxxxxxxxxxxx682.2 M
Net Profit Margin xxxxxxxxxxxxxxx29.81 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx12.88 %
Return on Invested Capital xxxxxxxxxxxxxxx11.66 %
Return on Assets xxxxxxxxxxxxxxx2.81 %
Return on Equity xxxxxxxxxxxxxxx12.88 %
Return on Total Capital xxxxxxxxxxxxxxx7.21 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx153.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx11,786 M
Long Term Debt xxxxxxxxxxxxxxx523 M
Total Debt xxxxxxxxxxxxxxx12,309 M
Goodwill - Gross xxxxxxxxxxxxxxx2,318 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx13,403 M
Price To Book Value xxxxxxxxxxxxxxx3.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx137.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.66 %
Cost of Goods Sold xxxxxxxxxxxxxxx40 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx396 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx17 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.4

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

07/07/2025

5

Sell

$69.10

-1.83%

UBS notes the ASX ended June with strong equity turnover, supported by geopolitical volatility, as June cash equities rose 20.8% year-on-year, lifting 2H25 growth to 19.4%, ahead of the 10.7% expected by consensus.

Futures volume growth, in contrast, stalled in June (-0.4% year-on-year), though still delivered 20.1% growth for 2H25, modestly ahead of consensus at 18.4%, observes the broker.

Capital raisings rebounded sharply, up 125% year-on-year in 2H25, and collateral balances rose 16% to $13bn.

Despite this solid activity, UBS makes slight EPS downgrades for FY25/26 and flags ongoing regulatory and cost risks related to the CHESS replacement project.

The broker maintains a Sell rating with an unchanged $69.10 price target, citing limited value appeal and a constrained 4% EPS compound annual growth rate (CAGR) over FY25–29.

FORECAST
UBS forecasts a full year FY25 dividend of 225.00 cents and EPS of 265.00 cents.
UBS forecasts a full year FY26 dividend of 232.00 cents and EPS of 272.00 cents.

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

10/07/2025

3

Neutral

$69.20

-1.69%

Jarden highlights a strong 2H finish to FY25 for ASX, supported by a 4.7% gain in the ASX200, heightened market volatility, and robust activity across equities, futures, and capital raisings.

Key metrics in H2 included a 19.4% lift in daily equity turnover, 20.1% growth in futures and options volumes, and a 125% surge in capital raisings. The latter was aided by the Chemist Warehouse/Sigma Healthcare ((SIG)) merger and the Virgin Australia ((VGN)) IPO.

Despite this momentum, Jarden remains cautious due to the outlook for elevated regulatory and compliance costs in FY26 and beyond, as well as higher depreciation and amortisation expenses post-FY27.

Jarden retains a Neutral rating and raises its target to $69.20 from $68.25.

FORECAST
Jarden forecasts a full year FY25 dividend of 226.50 cents and EPS of 266.70 cents.
Jarden forecasts a full year FY26 dividend of 228.50 cents and EPS of 268.90 cents.

ASX STOCK CHART